Beam Therapeutics (NASDAQ: BEAM) CMO sells 373 shares for tax withholding

Rhea-AI Filing Summary

Beam Therapeutics Inc. Chief Medical Officer Amy Simon reported an open-market sale of 373 shares of common stock at $34.73 per share. According to the disclosure, these shares were automatically sold in a non-discretionary transaction to cover tax withholding obligations upon vesting of restricted stock units granted under the 2019 Equity Incentive Plan. The sales were executed under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Simon directly holds 102,363 shares of Beam Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 373 shares ($12,954)

Net Sell 1 txn

Insider Simon Amy

Role Chief Medical Officer

Sold 373 shs ($13K)

Type	Security	Shares	Price	Value
Sale	Common Stock	373	$34.73	$13K

Holdings After Transaction: Common Stock — 102,363 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 373 shares Sale price: $34.73 per share Shares held after transaction: 102,363 shares +1 more

4 metrics

Shares sold 373 shares Open-market sale on June 30, 2026

Sale price $34.73 per share Price for the 373 shares sold

Shares held after transaction 102,363 shares Direct common stock holdings after June 30, 2026 sale

Transaction type Open-market sale (non-derivative) Form 4 code S, common stock

Key Terms

restricted stock units, Rule 10b5-1 trading plan, tax withholding obligations, 2019 Equity Incentive Plan

4 terms

restricted stock units financial

"upon the vesting of certain restricted stock units granted to the Reporting Person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1 trading plan regulatory

"The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

tax withholding obligations financial

"sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations"

2019 Equity Incentive Plan financial

"granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:05 PM Accepted by SEC EDGAR 07/02/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Amy

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		S(1)		373	D	$34.73	102,363	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on June 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

	By: /s/ Christine Bellon, Attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Beam Therapeutics (BEAM) report for Amy Simon?

Beam Therapeutics reported that Chief Medical Officer Amy Simon sold 373 common shares at $34.73 each. The shares were automatically sold to cover tax withholding on vested restricted stock units under the company’s 2019 Equity Incentive Plan.

Was Amy Simon’s Beam Therapeutics (BEAM) share sale discretionary or pre-planned?

The share sale was non-discretionary and pre-planned. The filing states the 373 shares were automatically sold to satisfy tax withholding obligations, executed pursuant to a Rule 10b5-1 trading plan adopted on May 19, 2023.

Why were 373 Beam Therapeutics (BEAM) shares sold by the CMO?

The 373 shares were sold to cover tax withholding obligations triggered by the vesting of restricted stock units granted on June 30, 2022. Such tax-related sales are mechanistic and tied to compensation rather than a discretionary portfolio decision.

How many Beam Therapeutics (BEAM) shares does Amy Simon hold after this transaction?

After the tax-related sale, Amy Simon directly holds 102,363 shares of Beam Therapeutics common stock. This indicates the transaction involved only a small portion of her overall reported equity position in the company.

What plan governed the restricted stock units in this Beam Therapeutics (BEAM) Form 4?

The restricted stock units that vested and triggered the tax sale were granted under the Beam Therapeutics Inc. 2019 Equity Incentive Plan. This plan provides equity-based compensation, such as RSUs, to the company’s employees and executives.